Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations

K-ras is currently accepted as the most frequently mutated oncogene in non-small cell lung cancer (NSCLC, including squamous carcinoma, adenocarcinoma, and large cell carcinoma). NSCLC patients with the K-ras mutation appear to be refractory to the majority of systemic therapies. In the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Wang, Shu, Su, Zeng-feng, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829747/
https://www.ncbi.nlm.nih.gov/pubmed/27095937
http://dx.doi.org/10.5114/wo.2016.58499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829747/
https://www.ncbi.nlm.nih.gov/pubmed/27095937
http://dx.doi.org/10.5114/wo.2016.58499

Ejemplares similares